explore -WSS

explore

author：Wikipedia 2025-10-01 02:27:28 - browse：138

An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT — Christine Kao/STAT

It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

Lobbying power of AI, software-enabled devices

Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Drug cartel violence flares in western Mexico after vigilante leader's killing

Wikipedia

focus

WSS

Vertex non

The biotech scorecard for Q3: 15 stock

Prescription digital therapeutics are key to pharma’s future

AstraZeneca lung cancer study comes in below expectations

FDA drug safety: Singulair case shows systemic surveillance flaws

Time to name cancers by genetics, not organ of origin, expert says

focus

explore

Lobbying power of AI, software-enabled devices

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

UpToDate has a racism problem: Dr. Stanley Goldfarb

Peter Hotez and the public health issue of online harassment

Cognito secures funding to test medical device for Alzheimer's

After affirmative action ruling, medical educators look to 'holistic review'

UpToDate has a racism problem: Dr. Stanley Goldfarb

Walensky prepares to leave CDC — and Congress — behind

UpToDate has a racism problem: Dr. Stanley Goldfarb

BioMarin wins approval for gene therapy to treat hemophilia A

Dexcom's push to bring CGM to type 2 diabetes patients

hotspot

Hubble vs. James Webb telescope images: See the difference

Security flaws in third

Time to name cancers by genetics, not organ of origin, expert says

Beware reading your test results before your doctor does

Time to name cancers by genetics, not organ of origin, expert says

What we need to know about Arena Bioworks

Wikipedia

focus

focus

Wikipedia